On Tuesday, Editas Medicine Inc (NASDAQ: EDIT) opened higher 7.54% from the last session, before settling in for the closing price of $1.99. Price fluctuations for EDIT have ranged from $0.91 to $4.54 over the past 52 weeks.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -1.48%. Company’s average yearly earnings per share was noted 31.18% at the time writing. With a float of $97.12 million, this company’s outstanding shares have now reached $97.62 million.
Editas Medicine Inc (EDIT) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Editas Medicine Inc is 0.51%, while institutional ownership is 45.44%. The most recent insider transaction that took place on Dec 03 ’25, was worth 1,535. In this transaction EVP, CHIEF SCIENTIFIC OFFICER of this company sold 713 shares at a rate of $2.15, taking the stock ownership to the 68,777 shares. Before that another transaction happened on Dec 03 ’25, when Company’s CEO sold 5,603 for $2.15, making the entire transaction worth $12,064. This insider now owns 269,087 shares in total.
Editas Medicine Inc (EDIT) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.55 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.33) by -0.22. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 31.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.82% during the next five years compared to -1.48% drop over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Check out the current performance indicators for Editas Medicine Inc (EDIT). In the past quarter, the stock posted a quick ratio of 2.86. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.38, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -1.13 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Compared to the last year’s volume of 2.22 million, its volume of 2.01 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 24.84%.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 7.34%, which indicates a significant decrease from 28.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1300 in the past 14 days, which was lower than the 0.2200 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.5100, while its 200-day Moving Average is $2.4000. Nevertheless, the first resistance level for the watch stands at $2.2000 in the near term. At $2.2500, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.3500. If the price goes on to break the first support level at $2.0400, it is likely to go to the next support level at $1.9400. Now, if the price goes above the second support level, the third support stands at $1.8800.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
There are currently 97,619K shares outstanding in the company with a market cap of 208.90 million. Presently, the company’s annual sales total 32,310 K according to its annual income of -237,090 K. Last quarter, the company’s sales amounted to 7,540 K and its income totaled -25,120 K.
